Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s portfolio-Antibiotic is primarily used for ...

Nana kept her grandkids out of foster care. Then the foreclosure notice arrived.

Texas officials promised to help Rochelle care for her grandkids after taking them from their parents. But the help she ...
News-Medical.Net on MSN

Study sheds light on the practice patterns of aerosol drug therapy in patients with ARDS

A new review led by Associate Professor Sanjay Singhal from Dr. Ram Manohar Lohia Institute of Medical Sciences sheds light ...

Liquidia Corporation (LQDA) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies Transcript

Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 ...

Most Medicare Advantage plans are free upfront. You still might not be able to afford one.

On the surface, a Medicare Advantage plan that charges no monthly premium seems like a better deal than original Medicare with a Medigap and Part D drug plan, which have monthly premiums but typically ...
Le Lézard

Savara Announces Proposed Public Offering

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of shares of its ...
Le Lézard

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock ...

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW ...